{
    "clinical_study": {
        "@rank": "26889", 
        "arm_group": [
            {
                "arm_group_label": "boron gel", 
                "arm_group_type": "Active Comparator", 
                "description": "diabetic foot ulcer care with formulation gel: addition of borate as sodium penta boric acid pentahydrate 3% (w/v) and two different copolymer as pluronic block namely F68 2% (w/v) and f127 2% (w/v)."
            }, 
            {
                "arm_group_label": "control gel", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo gel containing polymer of carbopol ultrex (1%)"
            }
        ], 
        "brief_summary": {
            "textblock": "Boron as a naturally occurring element has some metabolic and inflammatory actions. The\n      antibacterial activity against gram negative bacteria is also known. Boron deficiency is\n      shown to be related with impaired wound bone healing in rats. Therefore, special wound care\n      formulas containing boron may have some positive effect on wound healing of the patients\n      with diabetic foot ulcers."
        }, 
        "brief_title": "Effect of Local Application of Boron on Diabetic Foot Ulcers", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetic Foot Ulcer", 
        "condition_browse": {
            "mesh_term": [
                "Ulcer", 
                "Foot Ulcer", 
                "Diabetic Foot"
            ]
        }, 
        "detailed_description": {
            "textblock": "Local treatment of diabetic foot ulcers:\n\n        1. Classification of International Working Group of the Diabetic Foot (IWGDF)\n\n        2. pre-treatment measurements including diameter and area\n\n        3. pre-treatment laboratory values including fasting glucose, hemoglobin, hemoglobin A1c,\n           leucocyte count and c-reactive protein\n\n        4. pre-treatment wound culture\n\n        5. treatment either by placebo gel containing polymer of  carbopol ultrex (1%) or by\n           formulation gel: addition of borate as sodium penta boric acid pentahydrate 3% (w/v)\n           and two different copolymer as pluronic block namely F68 2% (w/v) and f127 2% (w/v).\n\n        6. post-treatment measurements and values"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  diabetic food ulcer classified byInternational Working Group of the Diabetic Foot\n             (IWGDF) as grade 1 and 2\n\n        Exclusion Criteria:\n\n          -  previous vascular surgery on the side that the ulcer is present\n\n          -  uncontrolled diabetes mellitus\n\n          -  presence of osteitis, abscess, osteomyelitis, gangrene on the side that the ulcer is\n             present\n\n          -  diabetic food ulcer classified byInternational Working Group of the Diabetic Foot\n             (IWGDF) as grade 3"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02087215", 
            "org_study_id": "BRDIAFOOTULCER"
        }, 
        "intervention": [
            {
                "arm_group_label": "boron gel", 
                "description": "application of a formulation gel: addition of borate as sodium penta boric acid pentahydrate 3% (w/v) and two different copolymer as pluronic block namely F68 2% (w/v) and f127 2% (w/v) to diabetic foot ulcers.", 
                "intervention_name": "boron gel", 
                "intervention_type": "Drug", 
                "other_name": "borate as sodium penta boric acid pentahydrate 3%"
            }, 
            {
                "arm_group_label": "control gel", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Tetrahydrozoline", 
                "Boron"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "diabetes mellitus", 
            "foot ulcer", 
            "boron", 
            "wound care"
        ], 
        "lastchanged_date": "March 13, 2014", 
        "number_of_arms": "2", 
        "official_title": "Prospective Randomized Study of Local Application of Boron on Diabetic Foot Ulcers: Effect of Healing Process", 
        "other_outcome": {
            "description": "improvement of inflammatory parameters in diabetic foot ulcers including leukocyte count, c-reactive protein and wound culture", 
            "measure": "improvement of inflammatory parameters in diabetic foot ulcers", 
            "safety_issue": "Yes", 
            "time_frame": "up to 4 weeks"
        }, 
        "overall_official": {
            "affiliation": "bezmialem vakif university faculty of medicine dept of general surgery", 
            "last_name": "mustafa hasbahceci, md", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Turkey: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "healing and complete epithelization of diabetic foot ulcer with regard to time in weeks; comparison with progression or regression of grades of the wound based on classification sytems of International Working Group of the Diabetic Foot (IWGDF) and area of the wound measured as square centimeter.", 
            "measure": "number of the participants with complete epithelization of diabetic foot ulcer", 
            "safety_issue": "Yes", 
            "time_frame": "up to 4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02087215"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Bezmialem Vakif University", 
            "investigator_full_name": "Mustafa Hasbahceci", 
            "investigator_title": "surgeon", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "development of local infective complications including osteitis, abscess, osteomyelitis and gangrene", 
            "measure": "number of participants in whom local infective complications develop in diabetic foot ulcer patients", 
            "safety_issue": "Yes", 
            "time_frame": "up to 4 weeks"
        }, 
        "source": "Bezmialem Vakif University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bezmialem Vakif University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}